Asynchronous Techniques for the Delivery of Empirically Supported Psychotherapies

Sponsor
Stony Brook University (Other)
Overall Status
Completed
CT.gov ID
NCT05122429
Collaborator
(none)
145
1
3
13.3
10.9

Study Details

Study Description

Brief Summary

The aim of this study is to test the feasibility, acceptability and efficacy of methods for delivering mental health support when real-time communication is not possible (e.g. on long duration space flights where communication lags of up to 45 minutes are anticipated). The investigators hypothesize that the two enhanced treatment conditions (i.e., those with therapist support) will outperform the online self-management program without support. The investigators also predict that outcomes for the two enhanced conditions will be comparable to those reported in the literature for in-person psychotherapy programs.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: e-Health Treatment
N/A

Detailed Description

The aim of this study is to test the feasibility, acceptability and efficacy of methods for delivering mental health support when real-time communication is not possible (e.g. on long duration space flights where communication lags of up to 45 minutes are anticipated). Participants will be healthy, high functioning adults (e.g., medical residents, postdoctoral fellows in the sciences, math, and engineering) who report elevated psychological distress, mood or anxiety symptoms. Participants will complete a self-guided online therapy program (MyCompass) and will be randomized to receive one of the following: (1) online therapy without therapist support, 2) online therapy plus therapist support via electronic text-based messaging (i.e., secure email), or 3) online therapy plus therapist support via video messaging. Outcomes will be evaluated weekly via online self-report measures of psychological distress, mood, anxiety, number of hours and quality of sleep, fatigue, and resiliency indicators (i.e., coping and mindfulness). The investigators will examine changes over time in outcomes across all three groups. The investigators hypothesize that the two enhanced treatment conditions (i.e., those with therapist support) will outperform the online self-management program without support. The investigators also predict that outcomes for the two enhanced conditions will be comparable to those reported in the literature for in-person psychotherapy programs.

Study Design

Study Type:
Interventional
Actual Enrollment :
145 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Asynchronous Techniques for the Delivery of Empirically Supported Psychotherapies
Actual Study Start Date :
Nov 6, 2017
Actual Primary Completion Date :
Dec 17, 2018
Actual Study Completion Date :
Dec 17, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: myCompass Only

Self-guided e-health treatment

Behavioral: e-Health Treatment
Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.

Experimental: myCompass + Delayed Text Therapy Support

Self-guided e-health treatment with delayed (44min) text support from a therapist.

Behavioral: e-Health Treatment
Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.

Experimental: myCompass + Delayed Video Therapy Support

Self-guided e-health treatment with delayed (44min) video support from a therapist.

Behavioral: e-Health Treatment
Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.

Outcome Measures

Primary Outcome Measures

  1. Functional impairment in work/school, social life, and family life change [Change from baseline at 6-weeks assessments, 1-weeks post treatment, and 1-month post treatment]

    Sheehan Disability Scale is a 3 item measure to assess functional impairment in work/school, social life, and family life.

  2. Symptoms of Depression, Stress, and Anxiety Change [Change from baseline at 6-weeks assessments, 1-week post treatment, and 1-month post treatment]

    Depression Anxiety and Stress Scale is a 21-item measure to assess the severity of Depression, Stress, and Anxiety.

Secondary Outcome Measures

  1. Sleep Quality Change [Change from baseline at 1-week post treatment and 1-month post treatment]

    The Pittsburgh Sleep Quality Index (PSQI) is a 19-item questionnaire that assesses seven components of sleep quality (subjective sleep quality, sleep latency, duration, efficiency, disturbances, use of sleep medication, and daytime dysfunction). Each component is rated on a 0-3 severity scale referring to the frequency of each disturbance, and yields a global score with a range of 0-21.

  2. Fatigue Severity Change [Change from baseline at 1-week post treatment and 1-month post treatment]

    The Fatigue Severity Scale (FSS) measures fatigue and its effects on functioning. The FSS is comprised of nine items rated on a Likert-type rating scale (1-7), where one indicates no impairment and seven indicates severe impairment.

  3. Treatment Satisfaction [1-week post treatment]

    The ARMS-12 measures confidence, comfortability, and perceptions towards the program. The ARMS-12 is comprised of 12 items rated on a Likert-type rating scale (1-7), where one indicates the how strongly the agree or disagree with the statement.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. 18+years old;

  2. Masters of Art degree or higher in social/biomedical(medicine)/physical science, engineering or mathematics

  3. current elevated distress as measured by the Depression Anxiety and Stress Scale, 21 item version(≥ 5 on DASS Depression Subscale OR ≥ 4 on DASS Anxiety Subscale OR ≥ 8 on DASS Stress Subscale) (DASS, Lovibond & Lovibond, 1995); and, (5) ≥ 5 on any subscale of the Sheehan Disability Scale (SDS, Sheehan 1983).

Exclusion Criteria:
  1. Any current or recent (i.e. past month) suicide ideation

  2. any history of suicide attempt (within past 5 years)

  3. serious mental illness (i.e., psychosis, mania)

  4. alcohol or substance dependency during the past 6 months

  5. serious medical problems (e.g., seizures, cancer)

  6. current participation in psychotherapy

  7. new use of psychoactive medications (i.e., benzodiazepines for less than 1 month or selective serotonin reuptake inhibitors [SSRIs], tricyclics, or serotonin-norepinephrine reuptake inhibitors [SNRIs] for less than 3 months).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mind-Body Clinical Research Center Stony Brook New York United States 11790

Sponsors and Collaborators

  • Stony Brook University

Investigators

  • Principal Investigator: Adam Gonzalez, PHD, Stony Brook University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Adam Gonzalez, Associate Professor, Stony Brook University
ClinicalTrials.gov Identifier:
NCT05122429
Other Study ID Numbers:
  • NNX15AN64G
First Posted:
Nov 16, 2021
Last Update Posted:
Nov 16, 2021
Last Verified:
Nov 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 16, 2021